SURVODUTIDE – 10 mg

Survodutide Canada , Survodutide is a dual glucagon and GLP-1 receptor agonist being studied for its ability to target fat loss and liver health at the same time.

Early clinical data shows significant reductions in both body weight and liver fat, putting it on the radar as one of the most promising next-gen compounds in metabolic research.

Buy Survodutide in Canada!: Survodutide Canada

• Fast, Discreet Shipping Across Canada
• Third-Party Lab Tested
• 99%+ Purity Guaranteed
• Price Match in Effect

Survodutide isn’t just another GLP-1, it’s a metabolic precision tool that is ideal for users who want fat loss with preserved lean mass, especially in performance or longevity-focused protocols.

Molecular Design

• Structure: Survodutide is a 29-amino acid peptide derived from glucagon, with key substitutions from GLP-1 and exendin-4 to enhance dual receptor binding

• Lipidation: A lysine side chain at position 24 is linked to a fatty diacid, extending plasma half-life and enabling once-weekly dosing

• Receptor Affinity:
  • GLP-1R EC₅₀ ≈ 20 pM (vs 5 pM for native GLP-1)
  • GCGR EC₅₀ ≈ 108 pM (vs 5 pM for native glucagon)
  • Mimics oxyntomodulin in dual receptor activation

Mechanism of Action

GLP-1 Receptor Activation

• Enhances insulin secretion in response to glucose
• Suppresses glucagon release
• Slows gastric emptying, increasing satiety
• Reduces appetite and caloric intake

Glucagon Receptor Activation

• Stimulates lipolysis and fat oxidation
• Increases energy expenditure via thermogenesis
• Promotes hepatic glucose output, balanced by GLP-1’s insulinotropic effects

Together, this dual action supports fat mass reduction without compromising lean mass, ideal for body recomposition.

Preclinical & Clinical Highlights

• Up to 19% body weight reduction in Phase II trials
• 64.5% fibrosis reduction in MASH (F2–F3 stages)
• Demonstrated efficacy in non-diabetic obesity, type 2 diabetes, and metabolic liver disease
• Cryo-EM studies show stable binding poses at both receptors, validating its dual agonist profile